Key takeaways
- >90% of Gaucher patients have type 1 (non-neuronopathic) disease · Nalysnyk 2016 (PMID 27762169)
- 1 in 12–15 Gaucher carrier frequency in the Ashkenazi Jewish population · Balwani 2010 (PMID 20837833)
- 21.4× lifetime Parkinson's disease risk ratio in type 1 Gaucher vs general population · Bultron 2010 (PMID 20177787)
Gaucher type 1 is a GBA1-driven multisystem disease concentrated in the Ashkenazi Jewish founder population — and the N370S genotype that predicts non-neuronopathic disease also carries a 20-fold Parkinson's risk.
Gaucher disease is an autosomal recessive lysosomal storage disorder caused by biallelic mutations in GBA1, producing deficient acid β-glucosidase (glucocerebrosidase) and accumulation of glucosylceramide in macrophages — the Gaucher cells that infiltrate spleen, liver, and bone marrow. Disease divides into three types by neurological involvement: type 1 (non-neuronopathic) accounts for more than 90% of patients; type 2 (acute neuronopathic, infantile, usually fatal in early childhood) and type 3 (chronic neuronopathic) are far rarer. Type 1 presents with splenomegaly, hepatomegaly, anemia, thrombocytopenia, and skeletal disease, not the primary CNS degeneration that defines types 2 and 3.
Genotype predicts phenotype. The N370S (c.1226A>G) variant, when present on at least one allele, is protective against neuronopathic disease and defines type 1; the L444P variant in the homozygous state is associated with neuronopathic types 2 and 3. Gaucher type 1 is markedly enriched in the Ashkenazi Jewish population, where carrier frequency is about 1 in 12–15 and disease frequency roughly 1 in 500–1,000, versus 0.70–1.75 per 100,000 in the general population. Penetrance is variable: prenatal carrier-screening cohorts show that most 'asymptomatic' N370S homozygotes in fact have measurable anemia, thrombocytopenia, splenomegaly, or bone marrow infiltration (Arch Intern Med 2010). Critically, GBA1 is the single most common genetic risk factor for Parkinson's disease, and diagnosed type 1 patients carry a lifetime PD risk ratio of 21.4 versus the general population (J Inherit Metab Dis 2010).
Gaucher disease types and GBA1 genotype–phenotype correlation
| Gaucher Type | Neurological Involvement | Share of Cases | Typical GBA1 Genotype | Key Features |
|---|---|---|---|---|
| Type 1 — non-neuronopathic | None (visceral & skeletal only) | >90% of cases | ≥1 N370S (c.1226A>G) allele | Splenomegaly, hepatomegaly, anemia, thrombocytopenia, bone disease; enriched in Ashkenazi Jews (~1 in 500–1,000) |
| Type 2 — acute neuronopathic | Severe, infantile-onset CNS | Rarest (<5%) | L444P homozygous / null / recombinant | Rapid neurodegeneration; typically fatal by age 2–4 |
| Type 3 — chronic neuronopathic | Progressive CNS, later onset | ~5% of cases | L444P homozygous | Oculomotor apraxia, seizures, plus visceral disease |
| Founder variant — N370S | Protective against neuronopathic disease | — | c.1226A>G heterozygous / homozygous | Ashkenazi carrier ~1 in 12–15; predicts type 1; variable penetrance |
Sources: Nalysnyk L et al. Hematology 2016 (PMID 27762169); Balwani M et al. Arch Intern Med 2010 (PMID 20837833); Bultron G et al. J Inherit Metab Dis 2010 (PMID 20177787).
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- What is the size and structure of the US Gaucher type 1 population, and how does the Ashkenazi Jewish founder burden concentrate prevalence? • General-population vs Ashkenazi Jewish prevalence and carrier frequency • founder-variant concentration • diagnosed and treated pool sizing for type 1
- How does GBA1 genotype — N370S versus L444P — predict the type 1 / type 2 / type 3 split and disease severity? • Genotype–phenotype correlation • N370S protection against CNS disease • L444P homozygosity and neuronopathic types • penetrance and severity variability
- Where do diagnostic delay and the GBA1–Parkinson's link create unmet need and screening opportunity? • Diagnostic delay drivers and misdiagnosis patterns • the 21.4-fold Parkinson's risk • carrier-screening and case-finding opportunities
What's inside
-
1 · Disease Biology & GBA1 Mutation Landscape 4 pp
- Biallelic GBA1 mutations cause deficient acid β-glucosidase, driving glucosylceramide accumulation in Gaucher cells that infiltrate spleen, liver and bone marrow
- N370S predicts protection against neuronopathic disease while L444P in the homozygous state is linked to types 2 and 3
-
2 · US Epidemiology & the Ashkenazi Jewish Founder Population 5 pp
- Ashkenazi Jewish carrier frequency runs about 1 in 12–15, with disease frequency roughly 1 in 500–1,000, versus 0.70–1.75 per 100,000 in the general population
- Prenatal carrier-screening cohorts show most 'asymptomatic' N370S homozygotes actually have measurable anemia, thrombocytopenia or splenomegaly
-
3 · Type 1 vs Type 2/3 — Genotype–Phenotype Correlation 4 pp
- Type 1 accounts for more than 90% of cases and lacks the CNS degeneration that defines type 2 and type 3
- Type 2 is rarest, under 5% of cases and typically fatal by age 2–4, while type 3 (about 5%) presents oculomotor apraxia and seizures alongside visceral disease
-
4 · Clinical Manifestations & Disease Burden 5 pp
- Type 1 presents with splenomegaly, hepatomegaly, anemia, thrombocytopenia and skeletal disease rather than primary CNS involvement
- Bone disease and cytopenias compound the visceral burden, driving much of the treatment-monitoring and quality-of-life impact
-
5 · Diagnostic Pathway & Delay Analysis 4 pp
- Variable penetrance means many 'asymptomatic' N370S homozygotes in fact have measurable anemia, thrombocytopenia or splenomegaly on closer testing
- Diagnostic delay and misdiagnosis patterns underlie the gap between genetic risk and confirmed, treated diagnosis
-
6 · The GBA1–Parkinson's Disease Link 4 pp
- GBA1 is the single most common genetic risk factor for Parkinson's disease, independent of Gaucher diagnosis
- Diagnosed Gaucher type 1 patients carry a lifetime Parkinson's disease risk ratio of 21.4 versus the general population
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx Gaucher Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous characterisation of the US Gaucher type 1 population. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, geography, and epidemiological focus.
- 2. Scoping callAXLRx analyst confirms subpopulation scope, data sources, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx assessment is built from primary regulatory sources (FDA Drugs@FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer and HTA documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US Gaucher Disease Landscape sources: Nalysnyk et al. Hematology 2016 (PMID 27762169) for epidemiology; Balwani et al. Arch Intern Med 2010 (PMID 20837833) for Ashkenazi Jewish carrier and homozygote frequency; Bultron et al. J Inherit Metab Dis 2010 (PMID 20177787) for the GBA1–Parkinson's link; and peer-reviewed GBA1 genotype–phenotype literature.
- Type 1 share (>90%) and general-population prevalence verified against Nalysnyk et al. Hematology 2016 (PMID 27762169)
- Ashkenazi Jewish carrier and homozygote frequency verified against Balwani et al. Arch Intern Med 2010 (PMID 20837833)
- 21.4-fold Parkinson's disease risk verified against Bultron et al. J Inherit Metab Dis 2010 (PMID 20177787)
- N370S / L444P genotype–phenotype correlation verified against peer-reviewed Gaucher genetics literature
Frequently asked questions
Epidemiology How common is Gaucher disease type 1 in the US?
Gaucher type 1 accounts for more than 90% of Gaucher cases. General-population prevalence is low, at roughly 0.70–1.75 per 100,000, but the disease is markedly enriched in the Ashkenazi Jewish population, where carrier frequency is about 1 in 12–15 and disease frequency roughly 1 in 500–1,000. Type 1 is nonetheless panethnic and occurs across all populations.
Genetics How does GBA1 genotype determine Gaucher disease type?
Gaucher disease is caused by biallelic GBA1 mutations. The N370S variant on at least one allele is protective against CNS disease and defines non-neuronopathic type 1; L444P in the homozygous state is associated with neuronopathic types 2 and 3. Penetrance varies widely — many N370S homozygotes labeled 'asymptomatic' in fact have measurable anemia, thrombocytopenia or splenomegaly on evaluation.
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model, and a 10–15 slide PowerPoint readout deck. An optional 60-minute analyst readout call is included with all deliveries.